Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Current Leases (2019 - 2025)

Regenxbio has reported Current Leases over the past 7 years, most recently at $8.3 million for Q4 2025.

  • Quarterly results put Current Leases at $8.3 million for Q4 2025, up 4.86% from a year ago — trailing twelve months through Dec 2025 was $8.3 million (up 4.86% YoY), and the annual figure for FY2025 was $8.3 million, up 4.86%.
  • Current Leases for Q4 2025 was $8.3 million at Regenxbio, down from $9.1 million in the prior quarter.
  • Over the last five years, Current Leases for RGNX hit a ceiling of $9.1 million in Q3 2025 and a floor of $1.3 million in Q3 2021.
  • Median Current Leases over the past 5 years was $6.5 million (2023), compared with a mean of $5.5 million.
  • Biggest five-year swings in Current Leases: tumbled 62.71% in 2021 and later skyrocketed 242.29% in 2022.
  • Regenxbio's Current Leases stood at $1.8 million in 2021, then skyrocketed by 242.29% to $6.0 million in 2022, then grew by 17.86% to $7.1 million in 2023, then rose by 11.8% to $7.9 million in 2024, then increased by 4.86% to $8.3 million in 2025.
  • The last three reported values for Current Leases were $8.3 million (Q4 2025), $9.1 million (Q3 2025), and $8.0 million (Q2 2025) per Business Quant data.